Research & Development
With cancer being a leading cause of death in the world today, innovative solutions are critical we invest 7% of our revenue in basic research in the field of oncology & biotechnology. At Relic Biotech each Drugs go through a long development and approval process. Before any drug can be prescribed to a patient, our researchers make sure the drug is safe and that it effectively treats cancer.
We have strategic alliance with few academic research institutes in the field of biotechnology and pharmacy in India and abroad. Every year our team of scientist screened 100s of academic research project & select few of them for advance basic research. Our research and development process begins with understanding the disease and selecting a target (usually a receptor site on a cell) that can potentially be affected by a drug molecule in the pre-clinical trial.
- The global investment in research and development (R&D) is staggering. In 2019 alone, organizations around the world spent $2.3 trillion on R&D-the equivalent of roughly 2 percent of global GDP-about half of which came from industry and the remainder from governments and academic institutions. What’s more, that annual investment has been growing at approximately 4 percent per year over the past decade. While the pharmaceutical sector garners much attention due to its high R&D spending as a percentage of revenues.
- At Relic Biotech all of us have an inner drive to innovate and discover newer ways of doing things. We have strategic alliance with few academic research institutes in the field of biotechnology and pharmacy. Every year our technical team of experts screened 100s of academic research project & select few of them for advance basic research in the field of oncology.